Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Team

Editorial Team

International

The policy and regulatory insights advantage for biopharma decision-makers around the globe.

Latest From Pink Sheet Team

In Case You Missed It … News On Cheaper CAR-Ts, EU Approval Records, And More

We clean out your Martin Luther King Day inbox so you don't have to.

In Case You Missed It: RWE, US FDA Commissioner Hearings, 2021 Approval Trends, And More

Start the new year by catching up with these key stories posted by the Pink Sheet in late December.

Health Technology Assessment Real-World Evidence

Pink Sheet Podcast: Califf Confirmation Hearing, COVID-19 Vaccine Changes, Cancer Drugs From China

Pink Sheet reporters and editors discuss US FDA commissioner nominee Robert Califf’s Senate confirmation hearing, new COVID-19 vaccine recommendations from the US CDC, and issues related to US approval of China-developed cancer drugs.

FDA Leadership

In Case You Missed It: China’s ‘Dual Circulation’ Policy, Fixing Safety Data ‘Overload,’ And More

We clean out your Thanksgiving inbox so you don't have to.

Pink Sheet Podcast: COVID-19 Boosters For Adults, Aduhelm And Part B, Califf For FDA Commissioner

Pink Sheet reporters and editors discuss the authorization of COVID-19 vaccine booster shots for all adults, Aduhelm’s impact on Medicare Part B and rejection by EMA, and the nomination of ex-FDA commissioner Robert Califf for another term.

Vaccines Neurology

Pink Sheet Podcast: Drug Price Negotiations, Kids COVID Vaccine Deployed, FDA Chief Scientist Leaves

Pink Sheet reporters and editors discuss the congressional agreement to allow Medicare drug pricing negotiation, the authorization of the Pfizer/BioNTech vaccine for children age 5 to 11, and the departure of the US FDA’s Chief Scientist.

Pricing Debate Vaccines
See All
UsernamePublicRestriction

Register